Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

415 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Innovations and challenges in melanoma: summary statement from the first Cambridge conference.
Atkins MB, Elder DE, Essner R, Flaherty KT, Gajewski TF, Haluska FG, Hwu P, Keilholz U, Kirkwood JM, Mier JW, Ross MI, Slingluff CL, Sondak VK, Sosman JA, Weinstock MA, King L. Atkins MB, et al. Among authors: keilholz u. Clin Cancer Res. 2006 Apr 1;12(7 Pt 2):2291s-2296s. doi: 10.1158/1078-0432.CCR-05-2560. Clin Cancer Res. 2006. PMID: 16609047
Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma.
Hauschild A, Agarwala SS, Trefzer U, Hogg D, Robert C, Hersey P, Eggermont A, Grabbe S, Gonzalez R, Gille J, Peschel C, Schadendorf D, Garbe C, O'Day S, Daud A, White JM, Xia C, Patel K, Kirkwood JM, Keilholz U. Hauschild A, et al. Among authors: keilholz u. J Clin Oncol. 2009 Jun 10;27(17):2823-30. doi: 10.1200/JCO.2007.15.7636. Epub 2009 Apr 6. J Clin Oncol. 2009. PMID: 19349552 Clinical Trial.
Addition of histamine to interleukin 2 treatment augments type 1 T-cell responses in patients with melanoma in vivo: immunologic results from a randomized clinical trial of interleukin 2 with or without histamine (MP 104).
Asemissen AM, Scheibenbogen C, Letsch A, Hellstrand K, Thorén F, Gehlsen K, Schmittel A, Thiel E, Keilholz U. Asemissen AM, et al. Among authors: keilholz u. Clin Cancer Res. 2005 Jan 1;11(1):290-7. Clin Cancer Res. 2005. PMID: 15671558 Clinical Trial.
Identification of a highly immunogenic HLA-A*01-binding T cell epitope of WT1.
Asemissen AM, Keilholz U, Tenzer S, Müller M, Walter S, Stevanovic S, Schild H, Letsch A, Thiel E, Rammensee HG, Scheibenbogen C. Asemissen AM, et al. Among authors: keilholz u. Clin Cancer Res. 2006 Dec 15;12(24):7476-82. doi: 10.1158/1078-0432.CCR-06-1337. Clin Cancer Res. 2006. PMID: 17189421
415 results